论文部分内容阅读
目的探究奈达铂、紫杉醇联合同期放疗治疗中晚期宫颈癌的临床效果。方法选取我院2013年1月-2014年2月收治的62例中晚期宫颈癌患者,随机分成观察组和对照组,各31例。两组患者均实行常规放射治疗,观察组在此之上,通过奈达铂和紫杉醇联合同期放疗治疗,比较两组临床疗效。结果两组生存率、复发转移率和毒副反应、近期疗效进行组间比较,观察组均明显优于对照组,差异有统计学意义(P<0.05)。观察组治疗总有效率为64.52%,对照组总有效率为45.16%,组间比较差异有统计学意义(P<0.05)。结论中晚期宫颈癌通过奈达铂、紫杉醇联合同期化疗治疗,临床疗效理想且能有效改善患者的生存率。
Objective To investigate the clinical efficacy of nedaplatin and paclitaxel combined with concurrent radiotherapy in the treatment of advanced cervical cancer. Methods Sixty-two patients with advanced cervical cancer admitted in our hospital from January 2013 to February 2014 were randomly divided into observation group and control group, with 31 cases in each group. The two groups of patients were treated with conventional radiotherapy, the observation group on top of this, through the combination of Nedaplatin and paclitaxel radiotherapy, the clinical efficacy of the two groups were compared. Results The survival rates, recurrence and metastasis rates, toxicity and side effects of the two groups were compared between groups. The observation group was significantly better than the control group (P <0.05). The observation group, the total effective rate was 64.52%, the control group, the total effective rate was 45.16%, there was significant difference between the two groups (P <0.05). Conclusion The advanced cervical cancer through nedaplatin, paclitaxel combined with concurrent chemotherapy, clinical efficacy and can effectively improve the survival rate of patients.